Treatment for Perimenopause Symptoms: Options to Discuss With Your Clinician

We may earn money or products from the companies mentioned in this post.

Educational information only. This article does not replace medical advice, diagnosis, or treatment. Discuss options with a qualified healthcare professional.

Perimenopause can feel like your body changed the rules overnight. One week your sleep is fine, the next you are awake at 3 a.m. with a soaked shirt and a racing mind.

Treatment for perimenopause symptoms covers a wide range, from therapy and cooling tricks to prescription pills and vaginal products. Conflicting advice can make it difficult to decide what to ask about first.

This guide sorts the options by symptom so you can walk into an appointment knowing what to ask.

Quick Answer: Treatment Is Individualized

Quick answer: Treatment depends on the symptom affecting you, your health history, contraception needs, and preferences. Options can include hormonal, nonhormonal prescription, behavioral, and vaginal treatments. Some product indications and trial findings concern postmenopausal women, so a clinician must assess their relevance during perimenopause. Concerning bleeding or severe symptoms should be assessed promptly.

Natural menopause is identified after 12 consecutive months without a period when another cause does not explain it. Hormonal contraception and certain procedures can make that marker harder to interpret.

Perimenopause and postmenopause are different stages. In perimenopause you can still ovulate and get pregnant, so advice written for postmenopausal women does not always fit.

Use current clinical guidance and the specific product label when discussing treatment. This overview separates general options from individual prescribing decisions. Medication information was checked on November 3, 2026; labels can change.

If you are still sorting out where you are in the transition, our perimenopause timing guide covers typical ages and stages.

Assessment, Symptom Tracking, and Other Possible Causes

Assessment starts with your symptom pattern, menstrual history, age, medicines, and medical history. For otherwise healthy people aged 45 or older with typical symptoms and cycle changes, NICE recommends identifying perimenopause without routine laboratory testing.

A single hormone measurement can be difficult to interpret during the transition. Testing can still be appropriate for younger people, atypical symptoms, pregnancy, or other possible causes. Hormonal contraception also affects interpretation; do not stop it simply to obtain a test without clinical advice.

Symptoms that can have another cause

Fatigue, poor sleep, palpitations, mood changes, and heavy periods can come from other conditions. These include:

Thyroid problems
Iron-deficiency anemia
Sleep apnea
Depression or anxiety disorders
Pregnancy
Medication side effects

Sometimes perimenopause and one of these happen together. Mentioning every symptom helps your clinician sort it out.

Track What You Can Without Delaying Care

A short log can help a clinician understand the pattern. Bring whatever information you have; do not postpone care to complete a fixed tracking period. Useful notes include:

Period dates, flow heaviness, and any spotting
Hot flash and night sweat frequency, plus what you were doing
When you fall asleep, when you wake, and how often
Mood and anxiety patterns, and whether they follow your cycle
Vaginal, sexual, and urinary symptoms
Everything you take, including supplements and over-the-counter products

A phone note works fine. Perfect records are not required.

Hot Flashes and Night Sweats: Options to Discuss

Clinicians call these vasomotor symptoms. They are often the main reason women look for help.

Hormonal options

Systemic hormone therapy is the most effective treatment for bothersome hot flashes. When systemic estrogen is used in someone with a uterus, endometrial protection generally requires an appropriate progestogen. Low-dose vaginal therapy is a different treatment category and is not used to treat hot flashes.

For some people who still need contraception, a clinician may consider a suitable hormonal contraceptive instead. Menopausal hormone therapy and birth control have different formulations, risks, and purposes; they should not be treated as interchangeable.

Individual clot, stroke, cancer, liver, migraine, smoking, and bleeding history can affect the discussion. A concern relevant to one hormonal method does not automatically apply identically to every other method.

In February 2026, the FDA approved labeling changes for an initial group of menopausal hormone products. This did not eliminate all risks, contraindications, or the need for individual assessment. Consult the specific product’s current label.

Nonhormonal prescription options

Fezolinetant (Veozah) is approved for moderate to severe vasomotor symptoms due to menopause. Its prescribing information carries a boxed warning about liver injury. Liver testing is required before treatment and during treatment, including monthly for the first three months and again at months six and nine. Interactions and kidney or liver conditions can make it unsuitable; the prescriber must review the complete label.

Elinzanetant (Lynkuet) received initial US approval in 2025 for moderate to severe vasomotor symptoms due to menopause. Its current label addresses drowsiness and daytime impairment, liver testing, seizure risk, and drug interactions. It is contraindicated in pregnancy, and pregnancy assessment and contraception requirements are particularly relevant to anyone who could still become pregnant.

Paroxetine (Brisdelle) is approved for moderate to severe vasomotor symptoms associated with menopause; it is not a treatment for psychiatric conditions in this formulation. Its label includes a boxed warning about suicidal thoughts and behaviors and warns about interactions, including possible reduction of tamoxifen effectiveness. Other antidepressant formulations and indications should not be confused with Brisdelle.

These medicines have menopause-related indications and clinical evidence that needs to be interpreted for the individual. Their labels do not establish that they are appropriate for every person experiencing irregular cycles during perimenopause.

Off-label options discussed in clinical guidance include certain SSRIs or SNRIs, gabapentin, and oxybutynin. Off-label means use outside the specific FDA-approved indication; it does not mean the treatment lacks any research. Benefits, side effects, interactions, and the reason for choosing a medicine need clinical review. The 2023 Menopause Society statement does not recommend clonidine for vasomotor symptoms, so it should not be grouped with the recommended options.

Behavioral options

Cognitive behavioral therapy and clinical hypnosis are evidence-supported nonhormone approaches. Discuss the treatment goals, including symptom bother and daily impact, rather than assuming every intervention changes hot-flash frequency in the same way.

For many women the bother is the main problem, so this still counts as relief.

Sleep Problems, Anxiety, and Mood Changes

Woman sitting on a bed beside a window at dawn with a notebook and water nearby

Night sweats can wreck sleep, though they are only one cause. Insomnia often continues even after the sweats improve.

Sleep apnea also becomes more common in midlife. Loud snoring, gasping at night, or morning headaches are worth mentioning.

Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is usually the first treatment option for long-term insomnia. It addresses sleep patterns and the thoughts and behaviors that can maintain insomnia; suitability and delivery can be discussed with a professional.

Many apps and online programs exist, and a clinician can refer you to one.

Over-the-counter sleep aids with diphenhydramine or doxylamine can cause next-day grogginess. Ask your clinician before using any sleep medicine for more than a short stretch.

Mood and anxiety

The Menopause Society describes increased vulnerability to depression during the transition, particularly with a prior depression history. Mood symptoms deserve their own assessment rather than being dismissed as hormones.

Treatment can include therapy, antidepressants, hormonal options in some cases, and attention to sleep. SSRIs and SNRIs sometimes help mood and hot flashes together, and a clinician may factor that in.

Seek help promptly for persistent low mood, panic, or difficulty functioning. For thoughts of suicide or self-harm in the United States, call 988 or text 988. Call 911 for immediate danger. Do not wait for a routine menopause appointment.

Vaginal Dryness, Painful Sex, and Urinary Symptoms

Clinicians call this group genitourinary syndrome of menopause. It includes dryness, burning, irritation, pain with sex, urgency, and repeat urinary tract infections.

Hot flashes tend to fade over time. Vaginal and urinary symptoms usually continue and often get worse without treatment.

These symptoms are worth discussing openly. Assessment can also identify infections, skin conditions, pelvic floor problems, or other causes that need a different approach.

Vaginal Treatments and a Separate Oral Option

Moisturizers and lubricants: Vaginal moisturizers and lubricants can help with dryness and painful sex. They serve different purposes; discuss product suitability if symptoms persist.
Low-dose vaginal estrogen: Local products can relieve vaginal symptoms with much less systemic exposure than systemic hormone therapy. Confirm the exact product, because not every estrogen product used vaginally is intended only for local effects. A breast cancer history requires an individualized discussion.
Vaginal prasterone (Intrarosa): Its label concerns moderate to severe painful intercourse due to menopausal vaginal atrophy and specifies postmenopausal use. It is contraindicated with undiagnosed abnormal genital bleeding and carries a warning about current or past breast cancer. It should not be presented as a routine option for every person in perimenopause.
Oral ospemifene (Osphena): This is an oral medicine, not a local vaginal treatment. Its label covers moderate to severe painful intercourse or vaginal dryness due to menopausal atrophy and includes boxed warnings concerning endometrial cancer and cardiovascular disorders. Pregnancy, unexplained bleeding, clot or stroke history, and cancer history require careful assessment.

For a history of estrogen-dependent breast cancer, ACOG recommends nonhormonal approaches first. Low-dose vaginal estrogen may be considered in selected circumstances after discussing risks and benefits; people taking aromatase inhibitors should involve their oncology team in shared decision-making.

Other points

Pelvic floor physical therapy can help with pain, tightness, and leakage.

Urinary urgency, burning, recurrent infections, or leakage need assessment rather than an assumption that estrogen changes explain them. Fever, back pain, or blood in the urine warrants prompt medical advice. A clinician can determine whether infection testing, pelvic floor care, local treatment, or another approach fits the cause.

Menstrual Changes, Contraception, and Concerning Bleeding

Cycles can get shorter, longer, lighter, heavier, or skip months. Some irregularity is normal in perimenopause.

Some bleeding patterns need a closer look.

Bleeding That Needs Assessment

Soaking through a pad or tampon every hour for several hours
Large clots, or dizziness, faintness, or shortness of breath with heavy bleeding
Periods closer than 21 days apart, bleeding longer than 7 days, or bleeding longer than is usual for you
Bleeding between periods or after sex
Any bleeding after 12 months without a period
A sudden, major change from your usual pattern

Seek emergency medical care for heavy bleeding accompanied by fainting, chest pain, shortness of breath, or severe dizziness. ACOG advises emergency care when pads or tampons need changing every hour for more than two hours with symptoms such as chest pain, shortness of breath, or lightheadedness. Do not wait to meet a time threshold if seriously unwell. Discuss other abnormal bleeding promptly.

A clinician may check for pregnancy, anemia, thyroid problems, fibroids, and polyps. In some cases they sample the uterine lining, since heavy or irregular bleeding in midlife occasionally points to changes in the endometrium.

Treatment options

ACOG describes several cause-dependent options for heavy bleeding, including appropriate hormonal contraceptives, tranexamic acid, NSAIDs, or procedures. These options have different contraindications and interactions; this is not an instruction to self-treat heavy bleeding or combine medicines.

Tell your clinician whether you want lighter bleeding or no bleeding.

Contraception is a separate topic

Pregnancy stays possible until menopause is confirmed. Many hormone treatments for symptoms do not prevent pregnancy.

Ask whether an appropriate contraceptive method could address both pregnancy prevention and a symptom-management goal. Stopping contraception depends on age, the method used, and how menopause is assessed; bleeding suppression can obscure the usual menstrual marker. Ask for a specific plan rather than applying a single rule to everyone.

Lifestyle Measures: General Health Versus Symptom Relief

Some habits protect your long-term health, and a smaller set has evidence for easing symptoms. Both groups are worth knowing.

Strong general health benefits

Regular exercise, including strength training, supports your bones, heart, mood, and sleep. Exercise has important general health benefits, but it should not be presented as an established hot-flash treatment.

Enough protein, calcium, and vitamin D from food supports bone health. Quitting smoking helps, since smoking links to worse hot flashes and earlier menopause.

Limiting alcohol often improves sleep, and alcohol can trigger hot flashes for some people.

Some symptom evidence

Cooling measures may improve comfort, but comfort strategies and proven treatments for hot flashes are different claims. Exercise, yoga, relaxation, and other habits can have general health value even when they are not recommended as vasomotor-symptom treatments in the 2023 nonhormone statement.

Weight management may be relevant for some individuals, but it should not be presented as a universal solution or a reason to delay other care. The plan should fit your health, preferences, and clinical circumstances.

Supplements: Research Limitations and Safety Considerations

Supplements get a lot of attention in forums, and the marketing often runs ahead of the research. Studies on black cohosh, soy isoflavones, red clover, evening primrose oil, and similar products are mixed. Many are small, short, or use different formulas.

The 2023 Menopause Society statement does not recommend supplements or herbal remedies for vasomotor symptoms. Our perimenopause supplement comparison explains why labels and study findings need careful interpretation.

Safety points to raise with your clinician:

Dietary supplements are not FDA-approved for safety and effectiveness before marketing.
NCCIH reports rare liver-injury cases involving products labeled as black cohosh, while noting that causation is uncertain.
St. John’s wort can interact with medicines, including birth control pills and antidepressants.
Soy and other plant estrogens may matter if you have a hormone-sensitive condition.
Compounded hormones are not dietary supplements. FDA-approved products containing hormones identical to those made by the body exist; the term bioidentical does not mean a compounded product is safer. ACOG does not recommend adjunct hormone tests for dosing compounded menopausal hormones.

Bring every bottle, or a photo of each label, to your appointment.

Quick Reference Table

This table sums up treatment for perimenopause symptoms by symptom, along with what clinicians usually consider. It is a starting point for conversation.

Symptom or concern	Options to discuss	Important considerations
Hot flashes and night sweats	Suitable systemic hormones or contraception; labeled or evidence-supported nonhormonal options; CBT or hypnosis	Individual eligibility, menopause-related indications, pregnancy potential, interactions and drug-specific monitoring
Persistent insomnia	CBT-I; assessment of night sweats or another sleep disorder	Avoid assuming every sleep problem is hormonal
Mood or anxiety symptoms	Mental health assessment, therapy, appropriate medication, sleep care	Depression history, interactions, and prompt help for safety concerns
Vaginal dryness or painful sex	Moisturizers, lubricants, selected local treatments; separate oral options when appropriate	Specific product indication, unexplained bleeding, cancer history and systemic versus local effects
Urinary symptoms	Assessment, possible infection testing, pelvic floor care or other cause-specific treatment	Exclude infection and other causes; persistent or severe symptoms need review
Heavy or irregular bleeding	Evaluation followed by cause-specific medicines or procedures	Pregnancy, anemia, structural causes and possible endometrial assessment; distinguish emergencies
Pregnancy prevention	An individually suitable contraceptive method	Menopausal symptom treatment is not necessarily contraception

Appointment Checklist, Goals, and Follow-Up

Hands writing in a notebook beside a paper calendar and glass of water

Before you settle on treatment for perimenopause symptoms, a little prep makes the visit go further.

What to bring

Your tracking notes and the top two or three symptoms you want help with
A list of medications, supplements, and past reactions
Personal and family history of breast cancer, clots, stroke, heart disease, osteoporosis, and early menopause
Whether you need contraception
Your preferences, such as hormonal or nonhormonal, daily pill or local treatment

Questions to ask

Could something besides perimenopause be causing this?
Which options fit my health history, and which do you advise against?
What side effects should I watch for, and what monitoring do I need?
How long should I try this before we reassess?
What would make you want to see me sooner?

Set a clear goal

Pick a goal you can measure, such as fewer night wakings or sex without pain. A vague goal like “feel normal” gives you nothing to check later.

Agree on a follow-up date, treatment goal, and reasons to contact the clinician sooner. Some treatments require a specific monitoring schedule that should not wait for a routine follow-up.

FAQs

Blood tests for perimenopause

Routine hormone testing is generally unnecessary for otherwise healthy people aged 45 or older with typical symptoms and cycle changes. Younger age, atypical symptoms, and the possibility of other conditions can change the assessment.

Tests may still check for thyroid problems, anemia, or pregnancy.

Hormone therapy while you still have periods

Sometimes it is an option. A clinician may suggest a low-dose birth control pill or another approach that fits perimenopause.

Standard menopause hormone therapy has mostly been studied in postmenopausal women.

Nonhormonal prescriptions and safety

They avoid hormone-specific risks and carry their own warnings and side effects. Which one is safer depends on your health history.

Vaginal estrogen versus systemic hormone therapy

Local products act mainly in the vaginal tissue and very little is absorbed. The risk discussion differs from systemic therapy.

How long symptoms last

It varies a lot. Hot flashes often last several years.

Vaginal symptoms can continue or worsen without treatment.

Conclusion

Treatment for perimenopause symptoms works best when it matches your symptoms, your health history, and your goals. Track what is happening, bring a short list of priorities, and ask about the full range of choices, including hormonal, nonhormonal, local, and behavioral options.

Heavy or unusual bleeding, severe mood changes, and thoughts of self-harm need appropriate prompt or emergency attention. Other new or persistent symptoms also deserve assessment. You are entitled to a plan that fits your medical history and priorities.

This article is for general education and is not medical advice. Drug approvals, labeling, and guidelines change, so confirm current information with your clinician and official sources such as the FDA, The Menopause Society, ACOG, and NIH.